Red Box Labs Majestic

Ostarine GTx, Inc. Developed for the treatment of conditions such as muscle wasting and osteoporosis. The company invested approximately $35 million in its development.

In August 2011, a double-blind, placebo-controlled phase II trial focused on older men and postmenopausal women. In this study, Ostarine showed statistically significant improvements in total lean body mass and physical function without androgenic negative side effects (usually occurring with steroid therapy).

In August 2013, GTx announced that Ostarine had failed in two Phase III clinical trials to treat wasting in people with lung cancer. Officials have also indicated that it plans to maintain Ostarine’s approval in Europe.

In 2016, GTx began Phase II trials to see if Ostarine was effective for treating stress urinary incontinence in women, but these trials failed to reach the primary endpoint in the ASTRID test in 2018.

A 12-week double-blind, placebo-controlled phase II clinical trial was conducted in 2006 to evaluate Ostarine in 120 healthy elderly men (>60 years) and postmenopausal women. The primary endpoint is total lean body mass as assessed by dual energy X-ray absorption, and the secondary endpoints include physical function, body weight, insulin resistance, and safety. Ostarine treatment resulted in statistically significant dose-dependent increases in total lean body mass (P < 0.001, 3 mg vs. placebo) and clinically significant. There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo). The incidence of adverse events was similar between treatment groups. Ostarine showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. This study concluded that Ostarine may be useful in the prevention and treatment of muscle wasting associated with cancer and other chronic diseases.

A clinical study conducted in 2007-2008 examined the effects of Ostarine on muscle wasting and physical function in cancer patients. 159 patients were analyzed for safety (placebo, n=52; Ostarine 1 mg, n=53; Ostarine 3 mg, n=54). The valuable efficacy population consisted of 100 participants (placebo, n=34; Ostarine 1 mg, n=32; Ostarine 3 mg, n=34). Compared to baseline, in both Ostarine groups (Ostarine 1 mg median 1 5 kg, range −2 1 to 12 6, p=0 0012; Ostarine 3 mg 1 0 kg, -4 8 to 11 5, p=0·046). The change in total lean body mass (median 0·02 kg, range –5·8-6·7) within the placebo group was not significant (p=0·88). The most common serious adverse events were progression of malignant neoplasm (8/ 52 [15%] placebo vs 53 five [9%] Ostarine 1 mg vs seven 54 [13%] Ostarine 3 mg), pneumonia (two [4%] vs two [4%] vs three [6%]), and febrile neutropenia (three [6% vs one [2%] vs none). None of these incidents were considered related to drug work. Both 1mg and 3mg of Ostarine resulted in increases in lean body mass in patients with advanced cancer, compared with baseline measurements. No significant change from baseline was noted in patients assigned placebo. Adverse events were generally very similar between groups, and this was consistent for patients receiving chemotherapy.

In the same clinical study (2007-2008) Ostarine also significantly reduced fasting glucose levels, and a trend towards reduction in blood insulin was observed. These effects resulted in a reduction in insulin resistance from baseline in the 1 mg and 3 mg treatment groups calculated according to HOMA-IR. Note, this type of reduction in insulin resistance was similar to that observed with metformin and glipizide, the drugs used to treat diabetes. Low levels of testosterone in men are associated with insulin resistance and type II diabetes, while testosterone therapy is known to improve metabolic parameters. This observation may have potential implications for the use of Ostarine in prediabetic or diabetic individuals, as is commonly seen in patients with chronic kidney disease, chronic obstructive pulmonary disease, or metabolic syndrome. Compared to placebo, Ostarine also decreased total cholesterol, HDL, and triglycerides.

ADVANTAGES OF OSTARINE ON ANABOLIC-ANDROGENIC STEROIDS
Ostarine (MK-2866) is selective and primarily intended for movement in muscles and bones. Due to this selectivity, it does not cause strong androgenic negative effects on other organs, unlike anabolic steroids.
Similar to anabolic steroids, Ostarine can help you achieve significant muscle gains, but has significantly less dangerous and unwanted side effects, and the potential health risks that steroid use can cause are many times lower than that:
Ostarine does not convert to Estrogens or Dihydrotestosterone
Ostarine does not cause gynecomastia
Ostarine does not cause significant retention of water and salts
Ostarine does not cause increased cortisol and estrogen levels
Ostarine Does not have a heavy load for the liver
Ostarine does not cause prostate enlargement.
Ostarine does not cause kidney disease
Ostarine does not cause acne and oily skin
Ostarine does not cause hair loss and baldness
Ostarine does not cause swollen face
Ostarine does not cause excessive facial or body hair (hirsutism).
Ostarine does not cause mood swings
Ostarine does not cause nervousness, irritability, depression, restlessness
Ostarine does not cause aggression, explosiveness and psychological problems.
Ostarine is extremely effective when administered orally (no injections needed)